Business context and reporting period
Agomab Therapeutics NV, a Belgian clinical-stage biotechnology company, filed this Form 6-K for October 2026. On October 1, 2026, it announced positive topline data from the STENOVA open-label extension study of ontunisertib in fibrostenosing Crohn’s disease. The press release is identified as Exhibit 99.1, but its study results are not included in the supplied filing text.
Financial and operating metrics
The supplied text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It also provides no numerical clinical results or detailed study outcomes.
Material changes versus prior period
The filing reports the positive topline study announcement but provides no prior-period comparison or details sufficient to assess the magnitude or significance of the results.
Outlook, risks, and filing notes
The company identifies the potential of ontunisertib and the expected initiation of the NOV-ERA Phase 2b study as forward-looking matters. It cautions that clinical data may be preliminary and may not reflect final results, and cites risks involving clinical and preclinical development, regulatory approvals, and global economic conditions. The filing says forward-looking statements reflect expectations as of the filing date and disclaims an obligation to update them except as required by law.
The 6-K and Exhibit 99.1 are incorporated by reference into the company’s Form S-8 registration statement, except for quotes by Philippe Wiesel, MD, and Florian Rieder, MD.
Important facts for investors to verify
- Review Exhibit 99.1 for the actual STENOVA results, including endpoints, effect sizes, safety findings, study population, and limitations.
- Check the company’s disclosures for the timing and plans for the NOV-ERA Phase 2b study and any regulatory interactions.
- Consult the company’s Form 20-F and subsequent SEC filings for financial position, cash runway, and fuller risk disclosures; those details are not provided here.